Page last updated: 2024-12-09
Methyl indole-5-carboxylate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 2737635 |
| CHEMBL ID | 109238 |
| CHEBI ID | 194927 |
| SCHEMBL ID | 103794 |
Synonyms (54)
| Synonym |
|---|
| AC-3031 |
| BB 0253734 |
| smr000686020 |
| MLS001250153 |
| methyl 1h-indole-5-carboxylate |
| ISUPSL100238 |
| inchi=1/c10h9no2/c1-13-10(12)8-2-3-9-7(6-8)4-5-11-9/h2-6,11h,1h |
| methyl indole-5-carboxylate, 99% |
| 1011-65-0 |
| methyl indole-5-carboxylate |
| I-2515 |
| indole-5-carboxylic acid methyl ester |
| STK503886 |
| AKOS000265192 |
| CHEMBL109238 |
| I0545 |
| CHEBI:194927 |
| 1h-indole-5-carboxylic acid methyl ester |
| A800341 |
| HMS2220E16 |
| bdbm93019 |
| indole-5-carboxylate |
| PB29029 |
| HMS3330O22 |
| FT-0620502 |
| SCHEMBL103794 |
| AM81120 |
| 1h-indole-5-carboxylic acid, methyl ester |
| SS-6027 |
| SY003617 |
| mfcd00153023 |
| DTXSID00372193 |
| methylindole-5-carboxylate |
| methyl-indole-5-carboxylate |
| DRYBMFJLYYEOBZ-UHFFFAOYSA-N |
| 5-methoxycarbonyl-1h-indole |
| methyl 5-indole-carboxylate |
| 5-(methloxycarbonyl)indole |
| methyl 5-indolecarboxylate |
| 5-methloxycarbonylindole |
| 5-methoxycarbonylindole |
| methyl-5-indole carboxylate |
| methyl 5-indole carboxylate |
| 5-(methoxycarbonyl)indole |
| 5-indolecarboxylicacidmethylester |
| Z1153206326 |
| CS-D1099 |
| indole-5-carboxylic acid methyl ester, 98% |
| BBL104415 |
| 5-indolecarboxylic acid methyl ester |
| BCP27016 |
| SB10354 |
| SY282727 |
| EN300-154351 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| indolyl carboxylic acid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (8)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 5.1714 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 12.2798 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 125.8920 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 79.4328 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.5623 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chymotrypsinogen A | Bos taurus (cattle) | Ki | 2,800.0000 | 0.9000 | 4.0000 | 8.7000 | AID1799873 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (19)
Molecular Functions (11)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | Chymotrypsinogen A | Bos taurus (cattle) |
| serpin family protein binding | Chymotrypsinogen A | Bos taurus (cattle) |
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (11)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Chymotrypsinogen A | Bos taurus (cattle) |
| serine protease inhibitor complex | Chymotrypsinogen A | Bos taurus (cattle) |
| intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
| cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
| interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (16)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1799873 | Kinetic Assay from Article 10.1021/bi00877a017: \\INTERACTION OF AROMATIC COMPOUNDS WITH ALPHA-CHYMOTRYPSIN. II. COMBINATION OF THE ISOMERIC INDOLE CARBOXAMIDES AND CARBOXYLATE IONS WITH THE ACTIVE SITE.\\ | 1965 | Biochemistry, Jan, Volume: 4 | INTERACTION OF AROMATIC COMPOUNDS WITH ALPHA-CHYMOTRYPSIN. II. COMBINATION OF THE ISOMERIC INDOLE CARBOXAMIDES AND CARBOXYLATE IONS WITH THE ACTIVE SITE. |
| AID73213 | Residual porcine GSK-3-alpha/beta kinase activity with L240C/N297Q mutant cytochrome P450 2A6 extract | 2004 | Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12 | Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis. |
| AID54188 | Residual Cyclin-dependent kinase 5-p35nck5a activity with L240C/N297Q mutant cytochrome P450 2A6 extract | 2004 | Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12 | Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.69) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||